SOPHiA GENETICS Zukünftiges Wachstum
Future Kriterienprüfungen 1/6
SOPHiA GENETICS is forecast to grow earnings and revenue by 10.6% and 15.2% per annum respectively. EPS is expected to grow by 11.9% per annum. Return on equity is forecast to be -75.2% in 3 years.
Wichtige Informationen
10.6%
Wachstumsrate der Gewinne
11.9%
EPS-Wachstumsrate
| Healthcare Services Gewinnwachstum | 30.6% |
| Wachstumsrate der Einnahmen | 15.2% |
| Zukünftige Eigenkapitalrendite | -75.2% |
| Analystenabdeckung | Low |
| Zuletzt aktualisiert | 23 Oct 2024 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Is SOPHiA GENETICS (NASDAQ:SOPH) A Risky Investment?
Oct 03
SOPHiA GENETICS SA (NASDAQ:SOPH) Just Reported, And Analysts Assigned A US$6.00 Price Target
Aug 09Investors Still Waiting For A Pull Back In SOPHiA GENETICS SA (NASDAQ:SOPH)
Aug 08SOPHiA GENETICS SA (NASDAQ:SOPH) Full-Year Results Just Came Out: Here's What Analysts Are Forecasting For This Year
Mar 09Sophia Genetics: Breakthrough Potential In A Cautious Healthcare Sector
Feb 12Here's Why We're Not Too Worried About SOPHiA GENETICS' (NASDAQ:SOPH) Cash Burn Situation
Dec 27Why Investors Shouldn't Be Surprised By SOPHiA GENETICS SA's (NASDAQ:SOPH) 35% Share Price Surge
Nov 09Is SOPHiA GENETICS (NASDAQ:SOPH) In A Good Position To Invest In Growth?
Aug 08Here's Why We're Watching SOPHiA GENETICS' (NASDAQ:SOPH) Cash Burn Situation
Dec 15SOPHiA GENETICS partnering with Boundless Bio on oncogene cancer therapies
Sep 21SOPHiA Genetics GAAP EPS of -$0.39 in-line, revenue of $11.7M misses by $0.25M
Aug 09We're Hopeful That SOPHiA GENETICS (NASDAQ:SOPH) Will Use Its Cash Wisely
Jul 01SOPHiA GENETICS SA (NASDAQ:SOPH) Just Reported Earnings, And Analysts Cut Their Target Price
Mar 18We Think SOPHiA GENETICS (NASDAQ:SOPH) Can Afford To Drive Business Growth
Mar 10Here's Why We're Not Too Worried About SOPHiA GENETICS' (NASDAQ:SOPH) Cash Burn Situation
Nov 24Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2026 | 101 | -49 | -17 | -16 | 4 |
| 12/31/2025 | 79 | -57 | -33 | -32 | 5 |
| 12/31/2024 | 66 | -59 | -59 | -56 | 5 |
| 6/30/2024 | 65 | -67 | -56 | -47 | N/A |
| 3/31/2024 | 64 | -73 | -57 | -48 | N/A |
| 12/31/2023 | 62 | -79 | -58 | -49 | N/A |
| 9/30/2023 | 59 | -69 | -58 | -48 | N/A |
| 6/30/2023 | 54 | -78 | -68 | -58 | N/A |
| 3/31/2023 | 51 | -82 | -77 | -67 | N/A |
| 12/31/2022 | 48 | -87 | -80 | -70 | N/A |
| 9/30/2022 | 45 | -95 | -84 | -75 | N/A |
| 6/30/2022 | 44 | -93 | -77 | -69 | N/A |
| 3/31/2022 | 42 | -86 | -73 | -65 | N/A |
| 12/31/2021 | 40 | -74 | -65 | -58 | N/A |
| 9/30/2021 | 37 | -63 | -58 | -52 | N/A |
| 6/30/2021 | 34 | -52 | -51 | -46 | N/A |
| 3/31/2021 | 30 | -41 | -39 | -35 | N/A |
| 12/31/2020 | 28 | -39 | -35 | -32 | N/A |
| 12/31/2019 | 25 | -34 | -35 | -32 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: SOPH is forecast to remain unprofitable over the next 3 years.
Ertrag vs. Markt: SOPH is forecast to remain unprofitable over the next 3 years.
Hohe Wachstumserträge: SOPH is forecast to remain unprofitable over the next 3 years.
Einnahmen vs. Markt: SOPH's revenue (15.2% per year) is forecast to grow faster than the US market (8.9% per year).
Hohe Wachstumseinnahmen: SOPH's revenue (15.2% per year) is forecast to grow slower than 20% per year.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: SOPH is forecast to be unprofitable in 3 years.